HIF hydroxylation and the mammalian oxygen-sensing pathway
Open accessThe DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Hypoxia refers to below-normal levels of oxygen in air, blood, or tissue.Tissue hypoxia leads to cellular dysfunction and ultimately can lead to cell death.Causes of tissue hypoxia include (a) decreased blood oxygenation (such as occurs in certain pulmonary disorders), (b) altered oxygen release from hemoglobin (associated with some hemoglobinopathies), and (c) impaired blood delivery leading to localized anemia (i.e., ischemia) as a result of low cardiac output or vascular obstruction.In order to adapt to hypoxia, mammals use a number of physiological responses.These include (a) increased production of erythropoietin (EPO), which augments the production of red blood cells; (b) induction of tyrosine hydroxylase, which facilitates the control of ventilation through the carotid body; and (c) the stimulation of new blood vessels by upregulation of VEGF (1).At the cellular level, hypoxia induces a number of metabolic changes that allow for continued energy generation despite decreased oxygen availability. Hypoxia-inducible factorOne of the most important factors in the cellular response to hypoxia is hypoxia-inducible factor (HIF), which transcriptionally activates genes encoding proteins that mediate adaptive responses to reduced oxygen availability.HIF is a heterodimer consisting of one of three α subunits (HIF1-α, HIF2-α, or HIF3-α) bound to the aryl hydrocarbon receptor nuclear translocator (ARNT), which is also known as HIF1-β.HIF-α is a member of the basic helix-loop-helix (bHLH) superfamily, in which the HLH domain mediates sub-unit dimerization while the basic domain binds to DNA.HIF-α, like some other bHLH family members, contains a Per/Arnt/Sim (PAS) domain that facilitates the heterodimerization of HIF-α with ARNT (2-4).HIF target genes play critical roles in metabolism, angiogenesis, cell proliferation, and cell survival.Examples of HIF target genes include VEGF, glucose transporter 1 (GLUT1), and EPO.HIF binds to the hypoxia-responsive element, which contains the core recognition sequence 5′-TACGTG-3′ (5), in the cis-regulatory regions of hypoxia-inducible genes.Transcriptional activation by HIF is linked to its ability to recruit coactivator proteins such as CREB-binding protein (CBP), p300, steroid receptor coactivator-1, and translation initiation factor 2 (6-8).Whereas changes in oxygen levels do not affect ARNT protein levels, hypoxia markedly increases the abundance of the HIF-α subunits (9-11).This increase is due primarily to protein stabilization.In some settings, hypoxia also leads to increased HIF1-α mRNA accumulation (12,13).von Hippel-Lindau disease von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that affects approximately 1 in 35,000 individuals.The syndrome was first described in 1894 by Collins, who observed two siblings with bilateral retinal angiomas (now also called hemangioblastomas) (14).Later, the disease was mapped to chromosome 3p25 (15), and the VHL gene itself was isolated in 1993 (16).VHL behaves as a classical tumor suppressor gene.Almost all individuals with a clinical diagnosis of VHL disease can be shown to harbor a germline mutation of the VHL gene, with tumor development linked to somatic inactivation or loss of the remaining wild-type allele (17).The cardinal features of VHL disease are blood vessel tumors of the retina and central nervous system.Other tumors associated with VHL disease include clear cell carcinomas of the kidney, pheochromocytoma, endolymphatic sac tumors, pancreatic islet cell tumors, and papillary cystadenomas of the epididymis (in males) or broad ligament (in females) (18).In addition, patients with VHL often develop multiple visceral cysts involving organs such as the pancreas and kidneys (18).Biallelic VHL inactivation also occurs commonly in patients with sporadic hemangioblastoma or renal cell carcinoma,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Since pVHL binding to the ODD domain is dependent on PHD activity (Kaelin, 2002;Safran and Kaelin, 2003)”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Safran and Kaelin, 2003
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Self-citationEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
HIF-1: mediator of physiological and pathophysiological responses to hypoxia
Semenza, G. L. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1474 · Cited by 1,822
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
Research works printed but not linked: 3
- Collins, E.T. 1894. Intra-ocular growth (two cases, brother and sister, with peculiar new growth, probably retinal, affecting both eyes). Trans. Ophthalmol. Soc. U. K. 14 :141-149.
- Clifford, S.C., Prowse, A.H., Affara, N.A., Buys, C.H., and Maher, E.R. 1998. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer. 22 :200-209. · DOI · Paper page
- Yang, J., Haworth, S., Steinberg, S., Rosenberg, S., and Novotny, W. 2002. A randomized double-blind placebo-controlled trail of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. 21 :15 (Abstr.).
Cited by
Items 101–200 of 375
Design and synthesis of a series of novel pyrazolopyridines as HIF 1-α prolyl hydroxylase inhibitors
Warshakoon, N. C., Wu, S., Boyer, A. S., Kawamoto, R. M., Renock, S., Xu, K., Pokross, M. E., Evdokimov, A. G., Zhou, S., Winter, C., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.017 · Cited by 77
Therapeutic options to target angiogenesis in human malignancies
Herbst, R. S. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.4.635 · Cited by 76
Martini, M., Teofili, L., Cenci, T., Giona, F., Torti, L., Rea, M., Foa, R., Leone, G., & Larocca, L. M. (2008) · Haematologica · doi:10.3324/haematol.13210 · Cited by 73
Martorell, L., Gentile, M., Rius, J., Rodríguez, C., Crespo, J., Badimón, L., & Martínez‐González, J. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00945-09 · Cited by 79
Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice
Heximer, S. P. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318099c · Cited by 73
Highet, A. R., Khoda, S. M.-E., Buckberry, S., Leemaqz, S., Bianco‐Miotto, T., Harrington, E., Ricciardelli, C., & Roberts, C. T. (2015) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2015.10.004 · Cited by 76
The Three A’s in Asthma – Airway Smooth Muscle, Airway Remodeling & Angiogenesis
Keglowich, L., & Borger, P. (2015) · The Open Respiratory Medicine Journal · doi:10.2174/1874306401509010070 · Cited by 86
Inhibition of mitochondrial respiration by the anticancer agent 2-methoxyestradiol
Hagen, T., D’Amico, G., Quintero, M., Palacios‐Callender, M., Hollis, V., Lam, F., & Moncada, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.204 · Cited by 77
Mucin 1 Oncoprotein Blocks Hypoxia-inducible Factor 1α Activation in a Survival Response to Hypoxia
Li, Y., Kharbanda, S. M., & Kufe, D. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m610156200 · Cited by 82
Guadall, A., Orriols, M., Rodríguez‐Calvo, R., Calvayrac, O., Crespo, J., Aledo, R., Martínez‐González, J., & Rodríguez, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.162917 · Cited by 86
Metabolic Regulation of Potassium Channels
Tang, X. D., Santarelli, L. C., Heinemann, S. H., & Hoshi, T. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.041002.142720 · Cited by 73
Egger, M., Schgoer, W., Beer, A., Jeschke, J., Leierer, J., Theurl, M., Frauscher, S., Tepper, O. M., Niederwanger, A., Ritsch, A., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7440com · Cited by 68
Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Nagle, D. G., & Zhou, Y. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777698783 · Cited by 77
Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel–Lindau-Deficient Renal Cancer
Meléndez‐Rodríguez, F., Roche, O., Sánchez‐Prieto, R., & Aragonés, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00214 · Cited by 72
The worldwide distribution of the VHL 598C>T mutation indicates a single founding event
Liu, E., Percy, M. J., Amos, C. I., Guan, Y., Shete, S., Stockton, D. W., McMullin, M. F., Polyakova, L. A., Ang, S. O., Pastore, Y. D., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2550 · Cited by 66
Regulation of Iron Homeostasis and Related Diseases
Li, Y., Huang, X., Wang, J., Huang, R., & Wan, D. (2020) · Mediators of Inflammation · doi:10.1155/2020/6062094 · Cited by 73
Dewangan, J., Srivastava, S., Mishra, S., Divakar, A., Kumar, S., & Rath, S. K. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.026 · Cited by 68
Kim, Y. S., Lee, H.-A., Lim, J. Y., Kim, Y., Jung, C.-H., Yoo, S.-H., & Kim, Y. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2014.02.006 · Cited by 71
Vitreous Mediators in Retinal Hypoxic Diseases
dell’Omo, R., Semeraro, F., Bamonte, G., Cifariello, F., Romano, M. R., & Costagliola, C. (2013) · Mediators of Inflammation · doi:10.1155/2013/935301 · Cited by 68
Kamiyama, H., Takano, S., Tsuboi, K., & Matsumura, A. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0642-z · Cited by 74
A novel series of imidazo[1,2-a]pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors
Warshakoon, N. C., Wu, S., Boyer, A. S., Kawamoto, R. M., Sheville, J., Renock, S., Xu, K., Pokross, M. E., Evdokimov, A. G., Walter, R., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.089 · Cited by 67
Post, D. E., Devi, N. S., Li, Z., Brat, D. J., Kaur, B., Nicholson, A. C., Olson, J. J., Zhang, Z., & Meir, E. G. V. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1432 · Cited by 72
Costagliola, C., Agnifili, L., Arcidiacono, B., Duse, S., Fasanella, V., Mastropasqua, R., Verolino, M., & Semeraro, F. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707176 · Cited by 64
Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study
Kyzas, P., Stefanou, D., Batistatou, A. K., & Agnantis, N. J. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.11.060 · Cited by 63
Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases
Liao, C., & Zhang, Q. H. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.04.003 · Cited by 67
Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment
Howie, D., Waldmann, H., & Cobbold, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00409 · Cited by 57
Emerging drugs: mechanism of action, mass spectrometry and doping control analysis
Thevis, M., Thomas, A., Kohler, M., Beuck, S., & Schänzer, W. (2009) · Journal of Mass Spectrometry · doi:10.1002/jms.1584 · Cited by 65
Regulation of ferrochelatase gene expression by hypoxia
Liu, Y. L., Ang, S. O., Weigent, D. A., Prchal, J. T., & Bloomer, J. R. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.03.027 · Cited by 60
Lebkuchen, A., Carvalho, V. M., Venturini, G., Salgueiro, J. S., Freitas, L. S., Dellavance, A., Martins, F. C., Lorenzi‐Filho, G., Cardozo, K. H. M., & Drager, L. F. (2018) · Scientific Reports · doi:10.1038/s41598-018-29727-6 · Cited by 64
Activation of HIF-prolyl Hydroxylases by R59949, an Inhibitor of the Diacylglycerol Kinase
Temes, E., Martín-Puig, S., Acosta‐Iborra, B., Castellanos, M. C., Feijoo‐Cuaresma, M., Olmos, G., Aragonés, J., & Landázuri, M. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414694200 · Cited by 64
Soberman, R. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18099 · Cited by 59
Birle, D. C., & Hedley, D. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2722 · Cited by 58
Cellular oxygen sensing, signalling and how to survive translational arrest in hypoxia
Fähling, M. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2008.01894.x · Cited by 57
Sun, D., Feng, J., Dai, C., Sun, L., Jin, T., Ma, J., & Wang, L. (2006) · American Journal of Nephrology · doi:10.1159/000094778 · Cited by 57
Warshakoon, N. C., Wu, S., Boyer, A. S., Kawamoto, R. M., Sheville, J., Renock, S., Xu, K., Pokross, M. E., Zhou, S., Winter, C., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.040 · Cited by 58
Succinate dehydrogenase-deficient gastrointestinal stromal tumors
Wang, Y., Gu, M.-L., & Ji, F. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i8.2303 · Cited by 61
Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology
Guo, J., Cheng, J., North, B. J., & Wei, W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.07.001 · Cited by 55
MITOCHONDRIAL CHOLESTEROL AND CANCER
García‐Ruiz, C., de la Rosa, L. C., Ribas, V., & Fernández-Checa, J. C. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.014 · Cited by 62
Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET
Huang, Y., Fan, J., Li, Y., Fu, S., Chen, Y., & Wu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731503 · Cited by 59
van der Wel, H., Ercan, A., & West, C. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500600200 · Cited by 53
Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Romano, M. R., & Costagliola, C. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.911284 · Cited by 49
PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives
Inuzuka, H., Liu, J., Wei, W., & Rezaeian, A.-H. (2022) · Acta Materia Medica · doi:10.15212/amm-2021-0001 · Cited by 48
Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression
Gordeuk, V. R., Miasnikova, G. Y., Sergueeva, A. I., Niu, X., Nouraie, M., Okhotin, D. J., Polyakova, L. A., Ammosova, T., Nekhai, S., Ganz, T., et al. (2011) · Blood · doi:10.1182/blood-2011-03-345512 · Cited by 51
Yang, X., Du, T., Wang, X., Zhang, Y., Hu, W., Du, X., Miao, L., & Han, C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.027 · Cited by 51
Inconsistent effects of acidosis on HIF-α protein and its target genes
Willam, C., Warnecke, C., Schefold, J. C., Kügler, J., Koehne, P. S., Frei, U. A., Wiesener, M. S., & Eckardt, K. (2005) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-005-1486-3 · Cited by 50
Wang, E., Zhang, C., Polavaram, N. S., Liu, F., Wu, G., Schroeder, M. A., Lau, J. S., Mukhopadhyay, D., Jiang, S., O’Neill, B. P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086102 · Cited by 53
McClain, D. A., Abuelgasim, K. A., Nouraie, M., Salomon-Andonie, J., Niu, X., Miasnikova, G., Polyakova, L. A., Sergueeva, A., Okhotin, D. J., Cherqaoui, R., et al. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0961-5 · Cited by 47
Resch, T., Pircher, A., Kähler, C. M., Pratschke, J., & Hilbe, W. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9332-9 · Cited by 49
Wolf, G., Schroeder, R., & Stahl, R. A. K. (2004) · American Journal of Nephrology · doi:10.1159/000080086 · Cited by 54
Dort, M. V., Rehemtulla, A., & Ross, B. D. (2008) · Current Computer - Aided Drug Design · doi:10.2174/157340908783769265 · Cited by 49
Hypoxia and Hypoxia-Inducible Factor Signaling in Muscular Dystrophies: Cause and Consequences
Nguyen, T.-H., Conotte, S., Belayew, A., Declèves, A., Legrand, A., & Tassin, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137220 · Cited by 49
Gene therapy of the ischemic lower limb — Therapeutic angiogenesis
Bobek, V., Taltynov, O., Pintérová, D., & Kološtová, K. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2006.03.009 · Cited by 55
Transcriptional Regulation of Serine/Threonine Kinase-15 (STK15) Expression by Hypoxia and HIF-1
Klein, A. M., Flügel, D., & Kietzmann, T. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-01-0042 · Cited by 49
Messenger RNA Turnover and its Regulation in Herpesviral Infection
Glaunsinger, B. A., & Ganem, D. E. (2006) · Advances in virus research · doi:10.1016/s0065-3527(06)66007-7 · Cited by 49
Tegley, C. M., Viswanadhan, V. N., Biswas, K., Frohn, M. J., Peterkin, T. A. N., Chang, C. W. T., Bürli, R. W., Dao, J. H., Veith, H., Rogers, N. E., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.031 · Cited by 47
Effects of nitric oxide on renal interstitial fibrosis in rats with unilateral ureteral obstruction
Sun, D., Wang, Y., Liu, C., Zhou, X., Li, X., & Xiao, A. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.04.018 · Cited by 44
Petrella, B. L., & Brinckerhoff, C. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-66 · Cited by 52
WEST, C., Wel, H. V. D., Sassi, S., & Gaucher, E. A. (2004) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2004.04.007 · Cited by 46
Ayrapetov, M. K., Xu, C., Sun, Y., Zhu, K., Parmar, K., D'Andrea, A. D., & Price, B. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026064 · Cited by 41
Targeting angiogenesis in cancer therapy.
Ichihara, E., Kiura, K., & Tanimoto, M. (2011) · Institutional Repositories DataBase (IRDB) · doi:10.18926/amo/47260 · Cited by 49
Tomašić, N., Piterkova, L., Huff, C., Bilić, E., Yoon, D., Miasnikova, G., Sergueeva, A., Niu, X., Nekhai, S. A., Gordeuk, V. R., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.070508 · Cited by 46
Nur77 upregulates HIF-α by inhibiting pVHL-mediated degradation
Kim, B.-Y., Kim, H., Cho, E., & Youn, H. (2008) · Experimental & Molecular Medicine · doi:10.3858/emm.2008.40.1.71 · Cited by 43
Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease
Małyszko, J., Małyszko, J. S., & Matuszkiewicz‐Rowińska, J. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1599358 · Cited by 43
Pringle, K. G., Kind, K. L., Thompson, J. G., & Roberts, C. T. (2007) · Placenta · doi:10.1016/j.placenta.2007.05.009 · Cited by 40
Design and synthesis of substituted pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors
Warshakoon, N. C., Wu, S., Boyer, A. S., Kawamoto, R. M., Sheville, J., Bhatt, R. T., Renock, S., Xu, K., Pokross, M. E., Zhou, S., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.026 · Cited by 39
Ramos, A. S. P., Chambergo, F. S., Bonaccorsi, E. D., Ferreira, A. J. S., Cella, N., Gombert, A. K., Tonso, A., & El-Dorry, H. A. (2006) · Biochemistry · doi:10.1021/bi052553y · Cited by 47
Zheng, L., Tian, J., Liu, D., Zhao, Y., Fang, X., Zhang, Y., & Liu, Y. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15055 · Cited by 38
Xie, L., Johnson, R. S., & Freeman, R. S. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200407079 · Cited by 43
Sharma, N. M., Cunningham, C., Zheng, H., Liu, X., & Patel, K. P. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003423 · Cited by 38
Management of VEGF-Targeted Therapy-Induced Hypertension
Caletti, S., Paini, A., Coschignano, M. A., Ciuceis, C. D., Nardin, M., Zulli, R., Muiesan, M. L., Salvetti, M., & Rizzoni, D. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0871-1 · Cited by 42
Bouthelier, A., & Aragonés, J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118733 · Cited by 42
Mechanisms Operative in the Antitumor Activity of Temozolomide in Glioblastoma Multiforme
Fisher, T., Galanti, G., Lavie, G., Jacob‐Hirsch, J., Kventsel, I., Zeligson, S., Winkler, R. E., Simon, A. J., Amariglio, N., Rechavi, G., et al. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e318157053f · Cited by 43
Role of Arginine 220 in the Oxygen Sensor FixL from Bradyrhizobium japonicum
Balland, V., Bouzhir-Sima, L., Kiger, L., Marden, M. C., Vos, M. H., Liebl, U., & Mattioli, T. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413928200 · Cited by 37
Uncovering the role of hypoxia inducible factor-1α in skin carcinogenesis
Nys, K., Maes, H., Dudek, A. M., & Agostinis, P. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.02.001 · Cited by 40
Thanigaimani, S., Kichenadasse, G., & Mangoni, A. A. (2011) · Current Vascular Pharmacology · doi:10.2174/157016111795495503 · Cited by 38
Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells
Poomthavorn, P., Wong, S. H. X., Higgins, S., Werther, G. A., & Russo, V. C. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0340 · Cited by 37
Letelier, P. J., García, P., Leal, P., Ili, C., Buchegger, K., Riquelme, I., Sandoval, A., Tapia, Ó., & Roa, J. C. (2013) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3182a318a9 · Cited by 36
Hypoxia-Inducible Factors: Post-translational Crosstalk of Signaling Pathways
Dimova, E. Y., & Kietzmann, T. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-738-9_13 · Cited by 37
Redox regulation of cytoskeletal dynamics during differentiation and de-differentiation
Gellert, M., Hanschmann, E.-M., Lepka, K., Berndt, C., & Lillig, C. H. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.10.030 · Cited by 38
Abu‐Farha, M., Niles, J., & Willmore, W. G. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-045 · Cited by 37
Succinate as a signaling molecule in the mediation of liver diseases
Chen, H., Jin, C., Xie, L. H., & Wu, J. H. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166935 · Cited by 38
Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity
Lü, L., Yang, Z., Zhu, B., Fang, S., Yang, X., Cai, W., Li, C., Ma, J., & Gao, G. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.07.008 · Cited by 34
The inhibition of factor inhibiting hypoxia-inducible factor (FIH) by β-oxocarboxylic acids
Banerji, B., Conejo‐García, A., McNeill, L. A., McDonough, M. A., Buck, M. R., Hewitson, K. S., Oldham, N. J., & Schofield, C. J. (2005) · Chemical Communications · doi:10.1039/b510707e · Cited by 37
The regulatory mechanisms of proline and hydroxyproline metabolism: Recent advances in perspective
Phang, J. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1118675 · Cited by 37
Sun, D., Ma, H., Han, H. X., Yin, Z., Liu, C., Feng, J., Zhou, X., Li, X., Xiao, A., & Yu, R. (2011) · Kidney & Blood Pressure Research · doi:10.1159/000330718 · Cited by 33
Wang, D., Mahmud, I., Thakur, V. S., Tan, S. K., Isom, D. G., Lombard, D. B., Gonzalgo, M. L., Kryvenko, O. N., Lorenzi, P. L., Tcheuyap, V. T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2926 · Cited by 40
Implications for preeclampsia: hypoxia-induced Notch promotes trophoblast migration
Perlman, B. E., Merriam, A. A., Lemenze, A. D., Zhao, Q., Begum, S., Nair, M., Wu, T., Wapner, R. J., Kitajewski, J., Shawber, C. J., et al. (2021) · Reproduction · doi:10.1530/rep-20-0483 · Cited by 35
Smith, I. F., Boyle, J. P., Green, K. N., Pearson, H. A., & Peers, C. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02212.x · Cited by 33
Medium Depth Influences O 2 Availability and Metabolism in Human RPE Cultures
Hass, D. T., Zhang, Q., Autterson, G. A., Bryan, R. A., Hurley, J. B., & Miller, J. M. L. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.14.4 · Cited by 34
HIF1α-dependent uncoupling of glycolysis suppresses tumor cell proliferation
Urrutia, A. A., Mesa‐Ciller, C., Guajardo-Grence, A., Alkan, H. F., Soro-Arnáiz, I., Vandekeere, A., Campos, A. M. F., Igelmann, S., Fernández-Arroyo, L., Rinaldi, G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114103 · Cited by 34
Sharma, N. M., Haibara, A. S., Katsurada, K., Nandi, S. S., Liu, X., Zheng, H., & Patel, K. P. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.16002 · Cited by 33
Mitochondria as targets in angiogenesis inhibition
Park, D., & Dilda, P. J. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.12.005 · Cited by 33
Applications of Molecular Imaging
Galbán, C. J., Galbán, S., Dort, M. E. V., Luker, G. D., Bhojani, M. S., Rehemtulla, A., & Ross, B. D. (2010) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385071-3.00009-5 · Cited by 33
Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?
Korpanty, G. J., Smyth, E. C., & Carney, D. N. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.11.11 · Cited by 31
A novel experimental hypoxia chamber for cell culture.
Wang, R., Jin, F., & Zhong, H. (2014) · Europe PMC (PubMed Central) · Cited by 29
Thevis, M., Kohler, M., Schlörer, N. E., & Schänzer, W. (2007) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2007.11.003 · Cited by 31
Singh, M., Devi, U., Roy, S., Gupta, P. S., Saraf, S. A., & Kaithwas, G. (2016) · Breast Cancer · doi:10.1007/s12282-016-0683-6 · Cited by 28
Wu, K. L., Miao, H., & Khan, S. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00096.2007 · Cited by 30
Sable, C., Aliyu, Z. Y., Dham, N., Nouraie, M. S., Sachdev, V., Sidenko, S., Miasnikova, G., Polyakova, L. A., Sergueeva, A., Okhotin, D. J., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.051839 · Cited by 32
Mitochondrial disorders in renal tumors
Hervouet, É., & Godinot, C. (2006) · Mitochondrion · doi:10.1016/j.mito.2006.03.003 · Cited by 30
Metadata
- Authors
- Safran, M., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaelin, William G.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-03-15
- Volume
- 111
- Issue
- 6
- Pages
- 779-783
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC153778
- OpenAlex
- W2047816152
- Cited by
- 365
- References
- 77
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 18 · 2022: 5 · 2021: 10 · 2020: 10 · 2019: 10 · 2018: 8 · 2017: 11 · 2016: 6 · 2015: 10 · 2014: 16 · 2013: 10 · 2012: 15
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- hypoxia-inducible factor, oxygen sensing, tissue hypoxia, hypoxia-inducible factor-1α, ARNT, bHLH transcription factors, PAS domain, hypoxia response element, transcriptional activation, erythropoietin, vascular endothelial growth factor, glucose transporter 1, angiogenesis
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Asparagine, DNA-Binding Proteins, von Hippel-Lindau Disease, Humans, Hydroxylation, Ligases, Nuclear Proteins, Oxygen, Proline, Repressor Proteins, Transcription Factors, Trans-Activators, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Apoptosis Regulatory Proteins, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.